miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer. Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.
“We would like to thank Arash Khazei for his leadership over the past two and a half years. There has been an immense amount accomplished in building the infrastructure and optimizing miraDry operations in preparation for significant global growth,” said Amber Edwards. “We are thrilled to have Rob Catlin join this dynamic team bringing broad commercial leadership experience in dermatologic and aesthetic categories. As a respected leader in the industry, Rob will help miraDry enter a new phase as we accelerate provider adoption and reach more patients to provide the relief they are seeking.”
“I look forward to taking miraDry to the next level, building on the incredible progress that has been made since 1315 Capital acquired the company. There is tremendous market opportunity to accelerate awareness and adoption both in the US and globally, as validated by miraDry’s 82% growth in China in 2023,” said Mr. Catlin. “miraDry remains the first and only FDA-Cleared permanent solution for axillary hyperhidrosis, and with 90% patient satisfaction we expect it to maintain its leadership position in the growing hyperhidrosis category.”
With over two decades of experience in the medical aesthetics and dermatology industry, Mr. Catlin brings a proven track record of performance, strategic leadership, and value creation to miraDry. He has led dynamic sales and marketing teams in the medical aesthetics category including the energy based medical device field, fostering a culture of excellence within organizations including Allergan, Ulthera (acquired by Merz), Medicis (acquired by Valeant Pharmaceuticals) and most recently Endo International.
